Pentadeca Arginate (PDA)

Also known as: PDA peptide

Pentadeca Arginate (PDA) is an arginate-salt analog structurally derived from the BPC-157 peptide sequence, marketed primarily for tissue repair applications. Its proposed mechanism of action is extrapolated from BPC-157, which is known to promote angiogenesis, modulate growth factors such as VEGF and TGF-β, and enhance fibroblast migration and collagen synthesis. However, PDA itself lacks independent mechanistic studies; the arginate modification is intended to improve solubility and stability, but no published data confirm whether this alters bioavailability or receptor interactions compared to the parent peptide. As of current literature, there are zero PubMed-indexed studies specifically investigating PDA. All claims regarding its efficacy in wound healing, gastrointestinal repair, or musculoskeletal recovery are based on analogies to BPC-157 or theoretical considerations. The peptide remains in an experimental stage, with no peer-reviewed evidence supporting its safety, pharmacokinetics, or therapeutic outcomes in humans or animal models. Given the absence of direct research, clinical relevance cannot be established. Any use of PDA is speculative and carries unknown risks, including potential off-target effects or lack of efficacy. Until independent, controlled studies are published, PDA should not be considered a validated therapeutic agent. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides